about
Multiple myeloma cancer stem cellsCancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction?Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms.ALDH1 activity identifies tumor-initiating cells and links to chromosomal instability signatures in multiple myeloma.Implications of heterogeneity in multiple myeloma.3'LIFE: a functional assay to detect miRNA targets in high-throughputCUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.Repurposing Drugs in Oncology (ReDO)-itraconazole as an anti-cancer agent.Nek2 is a novel regulator of B cell development and immunological response.CD138-negative myeloma cells regulate mechanical properties of bone marrow stromal cells through SDF-1/CXCR4/AKT signaling pathwayNEK2 mediates ALDH1A1-dependent drug resistance in multiple myelomaLow serum miR-19a expression as a novel poor prognostic indicator in multiple myeloma.Bruton tyrosine kinase is a therapeutic target in stem-like cells from multiple myelomaMicroRNA-451 regulates stemness of side population cells via PI3K/Akt/mTOR signaling pathway in multiple myeloma.Mitochondrial-Targeted Decyl-Triphenylphosphonium Enhances 2-Deoxy-D-Glucose Mediated Oxidative Stress and Clonogenic Killing of Multiple Myeloma CellsRepurposing Drugs in Oncology (ReDO)-diclofenac as an anti-cancer agentFOXM1 is a therapeutic target for high-risk multiple myeloma.A CD138-independent strategy to detect minimal residual disease and circulating tumour cells in multiple myeloma.Decreased ferroportin promotes myeloma cell growth and osteoclast differentiationParathyroid hormone receptor mediates the anti-myeloma effect of proteasome inhibitors.The role of SH3GL3 in myeloma cell migration/invasion, stemness and chemo-resistance.Blocking EZH2 methylation transferase activity by GSK126 decreases stem cell-like myeloma cells.Novel approaches to pediatric leukemia treatment.RARα2 and PML-RAR similarities in the control of basal and retinoic acid induced myeloid maturation of acute myeloid leukemia cellsBUB1B promotes multiple myeloma cell proliferation through CDC20/CCNB axis.A subset of CD20(+) MM patients without the t(11;14) are associated with poor prognosis and a link to aberrant expression of Wnt signaling.Predicting the impact of combined therapies on myeloma cell growth using a hybrid multi-scale agent-based model.Dynamic balance of multiple myeloma clonogenic side population cell percentages controlled by environmental conditions.MicroRNA-324-5p regulates stemness, pathogenesis and sensitivity to bortezomib in multiple myeloma cells by targeting hedgehog signaling.Anthelmintic pyrvinium pamoate blocks Wnt/β-catenin and induces apoptosis in multiple myeloma cells.
P2860
Q26752365-5B1371B3-19F5-440B-9E75-F3A3AEE868FEQ26785497-695E3D98-40E9-4588-8CB2-88DA803A7A0CQ27692033-778ED6BC-BD49-4E38-8ED3-842594804BEEQ33599165-BCEC75AE-6D6E-45BA-AFFB-1AE1AED1AC1AQ33914824-020C619D-7988-4FB3-9797-27177E3FA84BQ34248768-0FD28B0E-6AFC-4A7E-809C-AD12EB25B816Q34437996-F1140067-0760-433F-9FF5-93B4697489E6Q34474583-005D4130-DC6F-493B-A288-ABADC5866581Q34609883-81D2A6EC-BF9E-43C7-A0D5-7942BFA80B78Q34898664-25F05C22-D3B2-44AE-8F8A-7F720F8B8B92Q35067960-8D910CB7-DF7B-4C26-A161-FE0A1833B6E1Q35246395-9E695BDC-CBE1-4E7F-9D99-402D44D7549DQ35260732-CC2279BB-7FC4-4067-AA2F-D6BEA6AB4CD6Q35615252-6A21EB9C-A2EC-4294-8303-94C5136D6659Q36208283-88D450B1-B6F0-4EDF-8158-ECE6BB7FFB4DQ36483712-87860D9E-5B5E-457B-9652-59E62DB31057Q36783627-260D1432-B561-4AF1-A85F-26D7A1B8729FQ37032148-E2CA80ED-7D52-4982-9B94-4092B8BB1657Q37097239-F042DEBE-1D8E-4E1F-A4D8-6D84416EF03AQ37668104-F212F119-F1CB-4322-AE7F-7269425A67A8Q37687348-4E45E431-60B9-4F09-96F5-59F3E8FCC7B6Q37709478-B0BA173D-9850-4482-BFA2-726AC402C3D2Q38500371-E14F8682-F0B9-4214-9373-C199A5F176D9Q38758034-519BF700-82A7-42F0-94C3-D54459929E13Q38907905-CDB52BC7-D124-42B7-A1A3-7227D443DAD5Q41431793-2CD72774-9660-4643-B0B6-32FA0750E35DQ42316163-66A9190C-8B4F-404A-8BC4-23EED5256703Q43068239-DF9BA565-06FD-45F2-98A4-83E2299AECE7Q47804377-1A2F7B5F-8E7D-4D28-AF1E-84432073E456Q52649655-44095810-438E-441F-BBBF-4AF0545012D0
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 11 July 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
RARα2 expression confers myeloma stem cell features
@en
RARα2 expression confers myeloma stem cell features.
@nl
type
label
RARα2 expression confers myeloma stem cell features
@en
RARα2 expression confers myeloma stem cell features.
@nl
prefLabel
RARα2 expression confers myeloma stem cell features
@en
RARα2 expression confers myeloma stem cell features.
@nl
P2093
P2860
P1433
P1476
RARα2 expression confers myeloma stem cell features
@en
P2093
Dana Levasseur
Fenghuang Zhan
Giulia Tolomelli
Guido Tricot
Hongwei Xu
Jiliang Xia
Satyabrata Das
P2860
P304
P356
10.1182/BLOOD-2013-02-482919
P407
P577
2013-07-11T00:00:00Z